Want to take quizzes and track your credits?
The Pfizer/BioNTech (BNT162b2) SARS-CoV-2 mRNA vaccine demonstrated 95% efficacy after 2 doses during clinical trials.1 There are reports that individuals with previous SARS-CoV-2 infection elicit stronger antibody responses after 1 dose compared with individuals without prior infection.2- 4 Consequently, individuals with a documented prior COVID-19 infection may be sufficiently protected from reinfection after a single mRNA vaccine dose, which could free up availability of millions of additional doses. We evaluated the SARS-CoV-2 spike immunoglobin (Ig) G antibody levels after 1 and 2 BNT162b2 doses in previously infected individuals compared with those without previous infection.
Sign in to take quiz and track your certificates
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: May 27, 2021.
Published: August 6, 2021. doi:10.1001/jamanetworkopen.2021.19741
Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2021 Anderson M et al. JAMA Network Open.
Corresponding Author: James Moy, MD, Division of Allergy and Immunology, Department of Internal Medicine, Rush University Medical Center, 1725 W Harrison St, Ste 117, Chicago, IL 60612 (firstname.lastname@example.org).
Author Contributions: Drs Anderson and Moy had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Anderson, Landay, Cloherty, Moy.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Anderson, Landay, Cloherty, Moy.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Anderson, Moy.
Obtained funding: Cloherty, Moy.
Administrative, technical, or material support: Anderson, Stec, Cloherty, Moy.
Supervision: Anderson, Landay, Cloherty, Moy.
Conflict of Interest Disclosures: None reported.
Funding/Support: This work was supported by Abbott Diagnostics Division Research and Development funding.
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
You currently have no searches saved.
You currently have no courses saved.